Market Overview:
The global biosimilar insulin lispro market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising demand for affordable and quality healthcare products, and growing awareness about biosimilars. Based on type, the global biosimilar insulin lispro market can be segmented into pre-filled syringes and cartridges. The pre-filled syringe segment is expected to account for a larger share of the market than the cartridge segment during the forecast period. This can be attributed to factors such as ease of use and lower cost as compared with cartridges. Based on application, the global biosimilar insulin lispro market can be divided into hospitals, retail pharmacies, and others (including clinics and home care settings). The hospitals segment is expected to account for a larger share of the market than other segments during the forecast period. This growth can be attributed to increasing demand for affordable healthcare products in hospitals worldwide.
Product Definition:
A biosimilar insulin is a copy of a biologic drug that is manufactured using recombinant DNA technology. The biosimilar insulin lispro is used to treat diabetes mellitus in adults and children. It is a man-made form of the hormone insulin, which the body produces naturally to help control blood sugar levels.
Pre-filled:
Pre-filled syringes are used to inject insulin. They contain the exact amount of insulin required for a specific treatment and do not require any further doseing. The rapid increase in demand for pre-filled syringes is expected to drive the market growth during the forecast period. In addition, factors such as increasing incidence of diabetes due to aging, obesity and an unhealthy lifestyle coupled with rising awareness about advanced products are anticipated to propel market growth over the next few years.
Cartridge:
A cartridge is a device containing insulin in pre-filled auto-injector form. The main function of the cartridge is to reduce the preparation of different doses of insulin by eliminating some steps usually done with syringes and vials. The product has been designed for people who have difficulty in preparing proper dose from liquid formulations, including children and adults with diabetes type 1 or type 2.
The product comes in two types: disposable and reusable cartridges.
Application Insights:
The others segment held the largest share of more than 50.0% in 2017. The application includes home healthcare and other applications such as industrial, food and beverage, and animal feed among others. Home healthcare is expected to be the fastest-growing segment owing to increasing demand for lispro insulin from countries such as India, China, Thailand among others where diabetes is a major concern due to high incidences of obesity caused by sedentary lifestyle and poor dietary habits.
Biosimilars are considered as an alternative for patients who are allergic or intolerant to regular insulin therapy due to its hypo-glycemic properties that help maintain normal blood sugar levels in the body without causing any negative effects on overall metabolism like ketosis or hyperactivity which can be observed during conventional type 1 & 2 diabetes treatment with regular human insulins.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to high awareness levels regarding b-lispro and other biosimilars, availability of a well-established healthcare infrastructure, and presence of major players. Moreover, increasing incidence of type I diabetes is also expected to contribute toward regional growth. For instance, as per CDC estimates published in 2016 around 6 million Americans were living with diagnosed diabetes or had been newly diagnosed with type I between 2013 & 2015.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to factors such as improving healthcare facilities for patients suffering from Type 1 Diabetes (T1D) coupled with rising disposable income among individuals especially in developing countries like China & India which are major consumers of lispro insulin analogs globally along with Japan.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for biosimilar insulin lispro in the coming years.
- Rising awareness about biosimilars: There is a growing awareness among healthcare professionals and patients about the benefits of biosimilars over their branded counterparts. This is likely to boost the demand for biosimilar insulin lispro in the near future.
- Growing number of product approvals: The number of product approvals for biosimilar insulin lispro has been increasing in recent years, owing to its potential benefits over branded products. This is likely to fuel market growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Biosimilar Insulin Lispro Market Research Report
By Type
Pre-filled, Cartridge
By Application
Hospital, Retail Pharmacy, Others
By Companies
Sanofi, Gan&Lee, Geropharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
208
Number of Tables & Figures
146
Customization Available
Yes, the report can be customized as per your need.
Global Biosimilar Insulin Lispro Market Report Segments:
The global Biosimilar Insulin Lispro market is segmented on the basis of:
Types
Pre-filled, Cartridge
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Gan&Lee
- Geropharm
Highlights of The Biosimilar Insulin Lispro Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pre-filled
- Cartridge
- By Application:
- Hospital
- Retail Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biosimilar Insulin Lispro Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biosimilar insulin lispro is a type of insulin that is similar to regular human insulin but has been modified so it does not require a prescription from a doctor.
Some of the major companies in the biosimilar insulin lispro market are Sanofi, Gan&Lee, Geropharm.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biosimilar Insulin Lispro Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Biosimilar Insulin Lispro Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Biosimilar Insulin Lispro Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Biosimilar Insulin Lispro Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Biosimilar Insulin Lispro Market Size & Forecast, 2018-2028
4.5.1 Biosimilar Insulin Lispro Market Size and Y-o-Y Growth
4.5.2 Biosimilar Insulin Lispro Market Absolute $ Opportunity
Chapter 5 Global Biosimilar Insulin Lispro Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Biosimilar Insulin Lispro Market Size Forecast by Type
5.2.1 Pre-filled
5.2.2 Cartridge
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Biosimilar Insulin Lispro Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Biosimilar Insulin Lispro Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biosimilar Insulin Lispro Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biosimilar Insulin Lispro Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Biosimilar Insulin Lispro Analysis and Forecast
9.1 Introduction
9.2 North America Biosimilar Insulin Lispro Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Biosimilar Insulin Lispro Market Size Forecast by Type
9.6.1 Pre-filled
9.6.2 Cartridge
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Biosimilar Insulin Lispro Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Biosimilar Insulin Lispro Analysis and Forecast
10.1 Introduction
10.2 Europe Biosimilar Insulin Lispro Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Biosimilar Insulin Lispro Market Size Forecast by Type
10.6.1 Pre-filled
10.6.2 Cartridge
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Biosimilar Insulin Lispro Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Biosimilar Insulin Lispro Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Biosimilar Insulin Lispro Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Biosimilar Insulin Lispro Market Size Forecast by Type
11.6.1 Pre-filled
11.6.2 Cartridge
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Biosimilar Insulin Lispro Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Biosimilar Insulin Lispro Analysis and Forecast
12.1 Introduction
12.2 Latin America Biosimilar Insulin Lispro Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Biosimilar Insulin Lispro Market Size Forecast by Type
12.6.1 Pre-filled
12.6.2 Cartridge
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Biosimilar Insulin Lispro Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Biosimilar Insulin Lispro Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Biosimilar Insulin Lispro Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Biosimilar Insulin Lispro Market Size Forecast by Type
13.6.1 Pre-filled
13.6.2 Cartridge
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Biosimilar Insulin Lispro Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biosimilar Insulin Lispro Market: Competitive Dashboard
14.2 Global Biosimilar Insulin Lispro Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Gan&Lee
14.3.3 Geropharm
